U.S. Department of Transportation Federal Motor Carrier Safety Administration	
Individual's Name:	

A Federal agency may not conduct or sponsor, and a person is not required to respond to, nor shall a person be subject to a penalty for failure to comply with a collection of information subject to the requirements of the Paperwork Reduction Act unless that collection of information displays a current valid OMB Control Number. The OMB Control Number for this information collection is 2126-0006. Public reporting for this collection of information is estimated to be approximately 8 minutes per response, including the time for reviewing instructions, gathering the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: Information Collection Clearance Officer, Federal Motor Carrier Safety Administration, MC-RRA, 1200 New Jersey Avenue, SE, Washington, D.C. 20590.

INSULIN-TREATED DIABETES MELLITUS ASSESSMENT FORM

	INSUERV-TREATED DIABETES WELLETTUS ASSESSMENT FORM						
Name: DOB:							
Dr	iver's License Number (if applicable): State:						
Fed has abi clin det	This individual is being evaluated either to determine whether he/she meets the physical qualification standards of the Federal Motor Carrier Safety Administration (FMCSA) to operate a commercial motor vehicle or because the individual has recently experienced a severe hypoglycemic episode. A treating clinician should complete this form to the best of his/he ability based on his/her knowledge of the individual's medical history. Completion of this form does not imply that a treating clinician is making a medical certification decision to qualify the individual to drive a commercial motor vehicle. An determination as to whether the individual is physically qualified to drive a commercial motor vehicle will be made by certified medical examiner on FMCSA's National Registry of Certified Medical Examiners.						
	FMCSA defines a treating clinician as a healthcare professional who manages, and prescribes insulin for, treatment of the individual's diabetes mellitus as authorized by the healthcare professional's applicable State licensing authority.						
Ins	structions to the Individual:						
	When you are being evaluated prior to a medical certification examination, the certified medical examiner must receive this form and begin the examination no later than 45 calendar days after a treating clinician signs this form.						
	nen you are being evaluated after a severe hypoglycemic episode, you must retain this form and give it to the certified dical examiner at your next medical certification examination.						
Ins	sulin-Treated Diabetes Mellitus Diagnosis						
1.	Date insulin use began:						
Blo	ood Glucose Self-Monitoring Records						
2.	Has the individual maintained at least the preceding 3 months of ongoing blood glucose self-monitoring records while being treated with insulin that are measured with an electronic glucometer that stores all readings, records the date and time of readings, and from which data can be electronically downloaded? Yes No						
3.	Has the individual provided at least the preceding 3 months of electronic self-monitoring records while being treated with insulin from his/her glucometer to the treating clinician for review? Yes No						

1

^{**}This document contains sensitive information and is for official use only. Improper handling of this information could negatively affect individuals. Handle and secure this information appropriately to prevent inadvertent disclosure by keeping the documents under the control of authorized persons. Properly dispose of this document when no longer required to be maintained by regulatory requirements. **

U.S. Department of Transportation Federal Motor Carrier Safety Administration

Fed	leral Motor Carrier Safety Administration
Ind	ividual's Name:
	If no, provide details:
pe mo do	ote: The individual is not physically qualified to operate a commercial motor vehicle for up to the maximum 12-month riod until he/she provides a treating clinician with at least the preceding 3 months of electronic blood glucose self-onitoring records while being treated with insulin. At the certified medical examiner's discretion, the individual who es not possess at least the preceding 3 months of electronic blood glucose self-monitoring records while being treated th insulin may qualify to operate a commercial motor vehicle for up to but not more than 3 months.
4.	How many times per day is the individual testing his/her blood glucose?
5.	Is the individual compliant with blood glucose self-monitoring based on his/her specific treatment plan? YesNo
	Comments (if necessary):
Se	vere Hypoglycemic Episodes
6.	Has the individual experienced any severe hypoglycemic episodes within the preceding 3 months? FMCSA defines a severe hypoglycemic episode as one that requires the assistance of others, or results in loss of consciousness, seizure, or coma. YesNo
	If yes, provide date(s) of occurrence, whether the cause has been addressed, and associated details (attach additional pages as needed):
Не	emoglobin A1C (HbA1C) Measurements
7.	Has the individual had HbA1C measured intermittently over the last 12 months, with the most recent measure within the preceding 3 months? YesNo
	If yes, attach the most recent result.
Di	abetes Complications
8.	Does the individual have signs of diabetic complications or target organ damage? This information will be used by the certified medical examiner in determining whether the listed conditions would impair the individual's ability to safely operate a commercial motor vehicle.
	 a. Renal disease/renal insufficiency (e.g., diabetic nephropathy, proteinuria, nephrotic syndrome)? YesNo

OMB Control Number: 2126-0006 **Expiration Date:** 11/30/2021

2

If yes, provide the date of diagnosis, current treatment, and whether the condition is stable:

^{**}This document contains sensitive information and is for official use only. Improper handling of this information could negatively affect individuals. Handle and secure this information appropriately to prevent inadvertent disclosure by keeping the documents under the control of authorized persons. Properly dispose of this document when no longer required to be maintained by regulatory requirements. **

Indi	vidua	al's Name:
	b.	Diabetic cardiovascular disease (e.g., coronary artery disease, hypertension, transient ischemic attack, stroke, peripheral vascular disease)? YesNo
		If yes, provide the date of diagnosis, current treatment, and whether the condition is stable:
	c.	Neurological disease/autonomic neuropathy (e.g., cardiovascular, gastrointestinal, genitourinary)? YesNo
		If yes, provide the date of diagnosis, current treatment, and whether the condition is stable:
	d.	Peripheral neuropathy (e.g., sensory loss, decreased sensation, loss of vibratory sense, loss of position sense)? YesNo
		If yes, provide the date of diagnosis, location, type of involvement, current treatment, and whether the condition is stable:
	e.	Lower limb (e.g., foot ulcers, amputated toes/foot, infection, gangrene)?YesNo
		If yes, provide the date of diagnosis, current treatment, and whether the condition is stable:
	f.	Other? (specify condition)YesNo
		If yes, provide the date of diagnosis, current treatment, and whether the condition is stable:
Pro	gre	essive Eye Diseases
9.	Da	te of last comprehensive eye examination:
10.	reti	s the individual been diagnosed with either severe non-proliferative diabetic retinopathy or proliferative diabetic inopathy? _YesNo
	Ify	ves, provide date of diagnosis:

Street Address

^{**}This document contains sensitive information and is for official use only. Improper handling of this information could negatively affect individuals. Handle and secure this information appropriately to prevent inadvertent disclosure by keeping the documents under the control of authorized persons. Properly dispose of this document when no longer required to be maintained by regulatory requirements. **